In today’s evolving biotech landscape, companies are under increasing pressure to remain strategically flexible as they navigate paths to liquidity and growth. Whether pursuing a public listing or positioning for acquisition, preparation is critical to maximizing value and avoiding costly missteps.
This fireside chat by Alvarez & Marsal and featuring Brian Bock from Evaluate brings together industry veterans and thought leaders to unpack what “readiness” truly means across both IPO and M&A pathways, and how biotech leaders can proactively prepare for either (or both) outcomes.
The session will explore two distinct topics:
- IPO readiness, outlining how biotech companies should effectively plan for the transition to public markets—from timing and operational preparedness to investor positioning.
- M&A readiness, examining how companies can acclimate quickly to the rapidly evolving dynamics of the deal lifecycle and realize value while controlling risk.
The session will conclude with audience Q&A, offering attendees the opportunity to gain practical insights tailored to their own strategic priorities.
